EUCTR2006-001246-13-ES进行中（未招募）1 期
Estudio internacional, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos, para investigar si Trovax, añadido al tratamiento estándar de primera linea, prolonga la supervivencia de pacientes con adenocarcinoma renal de células claras localmente avanzado o metastásico. An international, randomised, double blind, placebo controlled, parallel group study to investigate whether TroVax®, added to first-line standard of care therapy, prolongs the survival of patients with locally advanced or metastatic clear cell renal adenocarcinoma. - TRIST
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 700
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Signed informed consent. The patient must be competent to give written informed consent and comply with the protocol requirements.
- •2. Locally advanced or metastatic, histologically proven clear cell renal carcinoma.
- •3. Primary tumour surgically removed (some residual advanced primary tumour may remain).
- •4. At least four weeks post surgery or radiotherapy.
- •5. First-line. No prior therapy for renal cancer except surgery or radiotherapy.
- •6. Measurable disease.
- •7. Aged 18 years or more.
- •8. Patient expected to survive a minimum of 12 weeks (i.e. in the opinion of the investigator there is a >90% probability that the patient will survive >12 weeks if treated with the selected standard of care).
- •9. Free of clinically apparent autoimmune disease (including no prior confirmed diagnosis or treatment for autoimmune disease including Systemic Lupus Erythematosis, Grave’s disease, Hashimoto’s thyroiditis, multiple sclerosis, insulin dependant diabetes mellitus or systemic (non-joint) manifestations of rheumatoid disease).
- •10. Total white cell count = 3 x 109/L and lymphocyte count =1 x 109/L.
- •11. Serum creatinine =1.5 times the upper limit of normal.
- •12. Bilirubin = 2 times the upper limit of normal and an SGPT of = 4 times the upper limit of normal.
- •13. Women must be either post menopausal, or rendered surgically sterile or, if of child bearing potential, must have been practising a reliable form of contraception (oral contraception + a barrier method) for at least three months prior to the first dose of TroVax® and must continue while they are being treated with TroVax®. Men must practise a reliable form of contraception (barrier or vasectomy) while they are being treated with TroVax®.
- •14. No acute changes on 12-lead ECG.
- •15. Ejection fraction documented as not less than 45% or no clinical suspicion that cardiac ejection fraction is less than 45%.(If clinical suspicion exists the ejection fraction should be measured according to local site procedures).
- •16. Karnofsky performance status of = 80%.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Cerebral metastases. (Known from previous investigations or clinically detectable).
- •2. Previous exposure to TroVax®.
- •3. Serious infections within the 28 days prior to entry to the trial.
- •4. Known to test positive for HIV or hepatitis B or C.
- •5. Life threatening illness unrelated to cancer.
- •6. History of allergic response to previous vaccinia vaccinations.
- •7. Known allergy to egg proteins.
- •8. Known hypersensitivity to neomycin.
- •9. Participation in any other clinical trial of a licensed or unlicensed drug within the previous 30 days or during the course of this trial.
- •10. Previous malignancies within the last 10 years other than successfully treated squamous carcinoma of the skin or in situ carcinoma of the cervix treated with cone biopsy.
- •11. Previous history of major psychiatric disorder requiring hospitalization or any current psychiatric disorder that would impede the patient's ability to provide informed consent or to comply with the protocol.
- •12. Oral corticosteroid use unless prescribed as replacement therapy in the case of adrenal insufficiency.
- •13. Ongoing use of agents listed in locally approved prescribing information as causing immunosuppression.
- •14. Prior history of organ transplantation.
- •15. Pregnancy or lactation.
研究者
相似试验
进行中（未招募）
不适用
Estudio internacional, aleatorizado, doble ciego, de fase 3 para evaluar la eficaciade XL184 frente a placebo en pacientes con cáncer medular tiroideo, no extirpable, localmente avanzado o metastásicoAn International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 versus Placebo in Subjects with Unresectable, Locally Advanced, or Metastatic Medullary Thyroid CancerEUCTR2008-002320-29-ESExelixis, Inc.315
进行中（未招募）
1 期
Estudio internacional, aleatorizado, doble ciego, controlado con placebo fase 3 para evaluar la eficacia y la seguridad de KIACTA^TM en la prevención de la disminución de la función renal en pacientes con amiloidosis AA.International Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of KIACTA^TM in Preventing Renal Function Decline in Patients With AA AmyloidosisEUCTR2010-022313-25-ESC.T. Development Switzerland SAR347
进行中（未招募）
不适用
Estudio internacional, aleatorizado, a doble ciego, controlado con placebo y de fase 2 de AMG 479 con exemestano o fulvestrant en mujeres posmenopáusicas que presentan cáncer de mama localmente avanzado o metastásico con receptor hormonal positivo.An International, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of AMG 479 with Exemestane or Fulvestrant in Postmenopausal Women with Hormone Receptor Positive Locally Advanced or Metastatic Breast CancerCáncer de mama localmente avanzado o metastásico con receptor hormonal positivoHormone Receptor Positive Locally Advanced or Metastatic Breast CancerMedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2007-006050-25-ESAmgen Inc.150
进行中（未招募）
1 期
Estudio internacional randomizado, doble ciego, con grupos de tratamiento paralelos para evaluar la seguridad y eficacia de ocrelizumab administrado en un régimen de una o dos infusiones, comparado con placebo, en pacientes con artritis reumatoide activa que manifiestan una respuesta inadecuada a tratamiento con metotrexato.A Randomized, Double-Blind, Parallel-Group, InternationalStudy to Evaluate the Safety and Efficacy of Ocrelizumab Givenas a Single Infusion or Dual Infusion Compared with Placebo inPatients with Active Rheumatoid Arthritis Who Have anInadequate Response to Methotrexate TherapyArtritis reumatoideMedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2007-005759-41-ESF. Hoffmann-La Roche Ltd
进行中（未招募）
不适用
Estudio internacional randomizado, doble ciego, con grupos de tratamiento paralelos para evaluar la seguridad y eficacia de Ocrelizumab comparado con placebo en pacientes con Artritis Reumatoide activa con respuesta inadecuada a terapia con anti-TNF-a.Artritis ReumatoideEUCTR2006-005330-20-ESF. Hoffmann-La Roche Ltd1,000